Pathology Discovery

Pathology Discovery

ISSN 2052-7896
Original Research

Differential expression of monocyte/macrophage markers between active and inactive stage of patients with Behçet's disease

Ju A Shim1,3†, Sungbin Cho2†, Dongsik Bang2, A.K.M. Mostafa Anower1,3, Do-Young Kim2, Suhyun Cho2 and Seonghyang Sohn1,3*

*Correspondence: Seonghyang Sohn

These authors contributed equally to this work.

1. Laboratory of Cell Biology, Ajou University Institute for Medical Sciences, Suwon 443-721, Republic of Korea.

Author Affiliations

2. Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.

3. Department of Biomedical Science, Ajou University Graduate School, Suwon 443-721, Republic of Korea.


Although the exact etiology of Behçet's disease (BD) remains unclear, a complex interaction between T cells and antigenpresenting cells is known to be involved in the immunopathogenesis of BD. This study aimed to identify differentially expressed cell surface markers of peripheral blood mononuclear cells (PBMCs) in active and inactive stage of BD patients. PBMCs were isolated from six healthy controls, eight inactive BD patients and five active BD patients. Different cell phenotypes were analyzed by flow cytometry, serum cytokine levels were detected by ELISA and the morphological structure of polymorphonuclear neutrophils (PMN) was revealed by transmission electron microscope (TEM). The CD11b monocyte marker was slightly decreased in active BD patients (91.5±10.9%) compared with healthy controls (97.5±1.3%), but was not different compared to inactive BD patients (88.8±12.2%). The CD14 monocyte marker was significantly increased in active BD patients (28.9±18.7%, p=0.05) and inactivate BD patients (30.8±21.4%, p=0.08) compared to healthy controls (11.1±3.7%). However, CD16 (FcγRIIIA) was higher in inactive BD patients (93.9±2.4%) than active BD patients (85.3±14%), and CD32 (FcγRII) was down-regulated in active BD patients (26.6±18.1%) compared to inactive BD patients (46.6±30.3%) and healthy controls (71.7±17.4%; p=0.002). Most surprisingly, the mannose receptor marker CD206 was highly expressed with significance in active BD patients (49.7±35.2%) compared to healthy controls (7.4±0.8%) (p=0.02) and inactive BD patients (4.7±3.1%) (p=0.007). In spite of the up-regulation of CD206 in active BD patients, interleukin-10 was markedly increased in the inactive state after improving medication than in the active state. All these findings show that differential surface expression of PBMCs between the inactive and active state of BD patients may influence changes of the disease state following treatment.

Keywords: Behçet's disease, monocyte/macrophage, active and inactive stage, surface markers

ISSN 2052-7896
Volume 1
Abstract Download